Warburg Pincus announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare from Nautic Partners, General Atlantic, and The Vistria Group
PANTHERx Rare is the leading independent rare pharmacy in the U.S. The company focuses on helping patients with rare diseases access, start, and stay on complex therapies while supporting manufacturers, prescribers, and other partners across the rare disease care ecosystem
Nautic Partners and PANTHERx <a href="https://healthylife7.com/join-trial-testing-new-drug-for-weight-management/” title=”Join Trial Testing New Drug for Weight Management”>management will remain significant shareholders following the transaction. The investment is intended to support PANTHERx’s continued growth as a rare disease care platform while preserving its independent, patient-first, and manufacturer-aligned model
PANTHERx pioneered the rare pharmacy model and has built deep therapy expertise across rare disease treatment journeys. The company provides high-touch support designed to remove barriers to care, improve therapy access, and help patients and families navigate complex treatment pathways
The investment from Warburg Pincus is expected to support continued innovation in rare disease care. PANTHERx said the partnership will help fund investments in people, capabilities, and technology as the company works to serve more rare disease patients across the U.S
Warburg Pincus said PANTHERx combines deep clinical specialization, high-touch service, strong manufacturer partnerships, and a proven management team. The firm sees rare disease care as one of the most important and fastest-growing areas of healthcare
The transaction is expected to close in the coming months, subject to customary closing conditions and regulatory approvals
Founded in Pittsburgh in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. The company is licensed in all 50 states and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care and Utilization Review Accreditation Commission
PANTHERx is also a nine-time winner of the MMIT Patient Choice Award for patient satisfaction, including the 2026 honor
Warburg Pincus has more than $105 billion in assets under management and more than 225 active portfolio companies. Since inception, the firm has invested over $20 billion in more than 190 healthcare companies globally, including The START Center for Cancer Research, Summit Health/CityMD, Simtra BioPharma Solutions, Polyplus, Modernizing Medicine, GHX, and Ensemble Healthcare Partners
Support: J.P. Morgan Securities served as financial advisor to Warburg Pincus. Centerview Partners and Goldman Sachs served as financial advisors to PANTHERx. Cleary Gottlieb served as legal counsel to Warburg Pincus. Ropes & Gray served as legal counsel to PANTHERx
“PANTHERx was built to help patients navigate complex rare therapy journeys with urgency and precision. We are grateful for the partnership and support from Nautic Partners, General Atlantic, and The Vistria Group, whose investment helped expand our impact for patients and shape the company we are today. We are excited to begin this next chapter with Warburg Pincus and Nautic Partners. This partnership reinforces our position as an independent, rare-focused pharmacy and supports continued investment in people, capabilities, and technology to help us serve more rare disease patients with the expertise and compassion that define PANTHERx.”
Bansi Nagji, CEO of PANTHERx Rare
“PANTHERx is a standout healthcare platform with an exceptional management team, proven execution, and deep specialization in one of the most important and fastest-growing areas of healthcare. The Company combines deep clinical specialization, high-touch service, and strong manufacturer partnerships. We look forward to partnering with Bansi and the PANTHERx team to support the Company’s continued growth and expand access to life-changing therapies for patients with rare diseases across the United States.”
T.J. Carella, Managing Director and Head of Healthcare at Warburg Pincus, and Adam Krainson, Managing Director at Warburg Pincus
“Since our initial investment, we have had the privilege of working alongside Bansi and the exceptional team at PANTHERx as they made a meaningful difference in the lives of rare disease patients and families. We are excited to continue this journey alongside Warburg Pincus and support the next chapter of PANTHERx.”
Chris Corey and Joe Anderson, Managing Directors at Nautic Partners
“PANTHERx is defined by its steadfast commitment to an underserved patient population. We are proud to have supported Bansi and the team in broadening access to critical therapies through greater scale, sustained innovation, and clinical rigor. We look forward to following the company’s continued impact in the years ahead.”
Justin Sunshine, Managing Director, and John LaDien, Principal at General Atlantic
“When we invested in PANTHERx, we saw a company with the unique potential to redefine the specialty pharmacy model for rare diseases. We are proud of what the team has built over the last four years, and we thank the management team and employees for their unwavering commitment to putting patients first and making a profound impact in the lives of those they serve.”
Mo Yang, Partner at The Vistria Group
